[go: up one dir, main page]

CY1114865T1 - Νεοι αναστολεις seh και η χρηση toyς - Google Patents

Νεοι αναστολεις seh και η χρηση toyς

Info

Publication number
CY1114865T1
CY1114865T1 CY20141100122T CY141100122T CY1114865T1 CY 1114865 T1 CY1114865 T1 CY 1114865T1 CY 20141100122 T CY20141100122 T CY 20141100122T CY 141100122 T CY141100122 T CY 141100122T CY 1114865 T1 CY1114865 T1 CY 1114865T1
Authority
CY
Cyprus
Prior art keywords
seh
compound
suspensions
relates
treatment
Prior art date
Application number
CY20141100122T
Other languages
English (en)
Inventor
Yun Ding
Reema K Thalji
Joseph Paul Marino Jr
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of CY1114865T1 publication Critical patent/CY1114865T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/46—Phenazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • C07D251/52—Two nitrogen atoms with an oxygen or sulfur atom attached to the third ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Η εφεύρεση αναφέρεται σε νέους αναστολείς sEH και στη χρήση τους στη θεραπεία νόσων οι οποίες διαμεσολαβούνται από το ένζυμο sEH. Ιδιαιτέρως, η εφεύρεση αναφέρεται σε ενώσεις σύμφωνα με τον τύπο I: όπου τα R1, R2, R4, R5, R6, Α, Β, Υ, Ζ, n και m ορίζονται κατωτέρω, και σε φαρμακευτικώς αποδεκτά άλατα τους. Οι ενώσεις της εφεύρεσης είναι αναστολείς sEH και μπορούν να χρησιμοποιηθούν στη θεραπεία νόσων οι οποίες διαμεσολαβούνται από το ένζυμο sEH, όπως η υπέρταση. Συνεπώς, η εφεύρεση αναφέρεται περαιτέρω σε φαρμακευτικές συνθέσεις οι οποίες περιέχουν μια ένωση της εφεύρεσης. Η εφεύρεση ακόμη περαιτέρω αναφέρεται σε μεθόδους αναστολής της sEH και θεραπείας παθήσεων συνδεόμενων με αυτήν με τη χρήση μιας ένωσης της εφεύρεσης ή μιας φαρμακευτικής σύνθεσης η οποία περιέχει μια ένωση της εφεύρεσης.
CY20141100122T 2007-10-11 2014-02-18 Νεοι αναστολεις seh και η χρηση toyς CY1114865T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97915407P 2007-10-11 2007-10-11
EP08838314.6A EP2214487B1 (en) 2007-10-11 2008-10-10 Novel seh inhibitors and their use

Publications (1)

Publication Number Publication Date
CY1114865T1 true CY1114865T1 (el) 2016-12-14

Family

ID=40549589

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141100122T CY1114865T1 (el) 2007-10-11 2014-02-18 Νεοι αναστολεις seh και η χρηση toyς

Country Status (29)

Country Link
US (2) US8173805B2 (el)
EP (1) EP2214487B1 (el)
JP (1) JP5372943B2 (el)
KR (1) KR101546111B1 (el)
CN (1) CN101896065B (el)
AU (1) AU2008310732B2 (el)
BR (1) BRPI0817542A2 (el)
CA (1) CA2702265C (el)
CO (1) CO6270285A2 (el)
CR (1) CR11423A (el)
CY (1) CY1114865T1 (el)
DK (1) DK2214487T3 (el)
DO (1) DOP2010000101A (el)
EA (1) EA018414B1 (el)
ES (1) ES2445444T3 (el)
HK (1) HK1141211A1 (el)
HR (1) HRP20140105T1 (el)
IL (1) IL204889A (el)
MA (1) MA31761B1 (el)
MX (1) MX2010003942A (el)
MY (1) MY157116A (el)
NZ (1) NZ584471A (el)
PL (1) PL2214487T3 (el)
PT (1) PT2214487E (el)
RS (1) RS53180B (el)
SI (1) SI2214487T1 (el)
UA (1) UA107444C2 (el)
WO (1) WO2009049157A1 (el)
ZA (1) ZA201002465B (el)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7994317B2 (en) 2006-11-03 2011-08-09 GlaxoSmithKline, LLC sEH inhibitors and their use
JP5372943B2 (ja) 2007-10-11 2013-12-18 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 新規ｓＥＨ阻害剤およびそれらの使用
US8008483B2 (en) 2007-10-11 2011-08-30 GlaxoSmithKline, LLC sEH inhibitors and their use
FR2948027A1 (fr) * 2009-07-17 2011-01-21 Merck Sante Sas Derives amines de dihydro-1,3,5-triazine pour leur utilisation dans le traitement des maladies associees a une ischemie et/ou une reperfusion
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US8809552B2 (en) * 2011-11-01 2014-08-19 Hoffmann-La Roche Inc. Azetidine compounds, compositions and methods of use
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
WO2015104422A1 (en) 2014-01-13 2015-07-16 Basf Se Dihydrothiophene compounds for controlling invertebrate pests
WO2015155129A1 (en) * 2014-04-07 2015-10-15 Basf Se Diaminotriazine compound
WO2016058544A1 (en) 2014-10-16 2016-04-21 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2020074549A1 (en) * 2018-10-10 2020-04-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and topical pharmaceutical compositions for the treatment of skin microvascular dysfunction
WO2024105225A1 (en) 2022-11-18 2024-05-23 Universitat De Barcelona Synergistic combinations of a sigma receptor 1 (s1r) antagonist and a soluble epoxide hydrolase inhibitor (sehi) and their use in the treatment of pain
WO2024105234A1 (en) 2022-11-18 2024-05-23 Universitat De Barcelona Dual inhibitors of sigma-1 receptor and soluble epoxide hydrolase and their use in the treatment of pain

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5420283A (en) 1993-08-02 1995-05-30 Pfizer Inc. Resolution of (R)-2-benzylsuccinic acid 4-[4-(N-t-butoxycarbonylmethylamino)-piperidine] amide
AU3127900A (en) 1998-12-23 2000-07-31 Du Pont Pharmaceuticals Company Thrombin or factor xa inhibitors
EP1334104A2 (en) 2000-07-07 2003-08-13 Neotherapeutics, Inc. Methods for treatment of drug-induced peripheral neuropathy and related conditions
US6451814B1 (en) 2000-07-17 2002-09-17 Wyeth Heterocyclic β-3 adrenergic receptor agonists
RU2264389C3 (ru) 2000-10-20 2018-06-01 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Азотсодержащие ароматические производные, их применение, лекарственное средство на их основе и способ лечения
US20020091133A1 (en) 2000-12-12 2002-07-11 Eve M. Taylor Use of 9-substituted purine analogues and other molecules to stimulate neurogenesis
US6653301B2 (en) 2000-12-21 2003-11-25 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
EP1406892B1 (en) 2001-06-29 2007-09-05 Boehringer Ingelheim Pharmaceuticals Inc. Phenyl pyrazole derivatives as soluble epoxide hydrolase inhibitors
US20030055249A1 (en) 2001-07-17 2003-03-20 Fick David B. Synthesis and methods of use of pyrimidine analogues and derivatives
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
PT1479397E (pt) 2002-02-05 2011-09-01 Astellas Pharma Inc Derivados de 2,4,6-triamino-1,3,5-triazina
JP2005532321A (ja) 2002-05-16 2005-10-27 ファルマシア コーポレーション 呼吸器の疾患および状態の、選択的ｉＮＯＳ阻害剤とＰＤＥ阻害剤による治療方法、ならびにそのための組成物
US20050197350A1 (en) 2003-03-31 2005-09-08 Taisho Pharmaceutical Co., Ltd. Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof
AU2004253962A1 (en) 2003-07-02 2005-01-13 Vertex Pharmaceuticals Incorporated Pyrimidines useful as modulators of voltage-gated ion channels
WO2005028467A1 (en) * 2003-09-15 2005-03-31 Anadys Pharmaceuticals, Inc. Antibacterial 3,5-diaminopiperidine-substitute aromatic and heteroaromatic compounds
ATE547404T1 (de) 2003-09-22 2012-03-15 Msd Kk Piperidinderivate
GB0401269D0 (en) 2004-01-21 2004-02-25 Astrazeneca Ab Compounds
US20060069110A1 (en) 2004-09-27 2006-03-30 Andersen Denise L Substituted heterocyclic compounds and methods of use
TW200628463A (en) 2004-11-10 2006-08-16 Synta Pharmaceuticals Corp Heteroaryl compounds
US20060142572A1 (en) 2004-12-14 2006-06-29 Gabriel Martinez-Botella Inhibitors of ERK protein kinase and uses thereof
WO2006121719A2 (en) 2005-05-06 2006-11-16 Boehringer Ingelheim International, Gmbh Soluble epoxide hydrolase inhibitors and methods of using same
JP2009511489A (ja) * 2005-10-07 2009-03-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 可溶性エポキシド加水分解酵素阻害剤として有益なｎ−置換ピリジノン又はピリミジノン化合物
CA2637620A1 (en) * 2006-02-16 2007-08-30 Boehringer Ingelheim International Gmbh Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors
TW200808723A (en) 2006-03-13 2008-02-16 Univ California Conformationally restricted urea inhibitors of soluble epoxide hydrolase
US7994317B2 (en) * 2006-11-03 2011-08-09 GlaxoSmithKline, LLC sEH inhibitors and their use
US8008483B2 (en) 2007-10-11 2011-08-30 GlaxoSmithKline, LLC sEH inhibitors and their use
JP5372943B2 (ja) 2007-10-11 2013-12-18 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 新規ｓＥＨ阻害剤およびそれらの使用
WO2009049154A1 (en) 2007-10-11 2009-04-16 Smithkline Beecham Corporation NOVEL sEH INHIBITORS AND THEIR USE
JPWO2009048154A1 (ja) 2007-10-12 2011-02-24 日本電気株式会社 半導体装置及びその設計方法
WO2009070497A1 (en) 2007-11-28 2009-06-04 Smithkline Beecham Corporation SEH AND 11 β-HSD1 INHIBITORS AND THEIR USE
EP2224928A4 (en) 2007-12-06 2012-02-15 Glaxosmithkline Llc NOVEL INHIBITORS OF SEH AND THEIR USE
EP2240021A4 (en) 2008-01-30 2011-08-17 Glaxosmithkline Llc NEW SEH-HEMMER AND ITS USE
WO2009097476A1 (en) 2008-01-30 2009-08-06 Smithkline Beecham Corporation NOVEL sEH INHIBITORS AND THEIR USE
US20100311775A1 (en) 2008-01-30 2010-12-09 Smithkline Beecham Corporation Novel sEH Inhibitors and Their Use
WO2010011917A1 (en) 2008-07-25 2010-01-28 Glaxosmithkline Llc SEH AND 11β-HSD1 DUAL INHIBITORS

Also Published As

Publication number Publication date
US8212032B2 (en) 2012-07-03
HK1141211A1 (en) 2010-11-05
AU2008310732B2 (en) 2012-03-08
KR20100075619A (ko) 2010-07-02
CN101896065A (zh) 2010-11-24
CA2702265A1 (en) 2009-04-16
EP2214487A4 (en) 2011-12-21
MX2010003942A (es) 2010-04-30
ES2445444T3 (es) 2014-03-03
CO6270285A2 (es) 2011-04-20
DOP2010000101A (es) 2010-07-31
US20100210656A1 (en) 2010-08-19
MY157116A (en) 2016-05-13
EA201070442A1 (ru) 2010-10-29
IL204889A0 (en) 2010-11-30
DK2214487T3 (da) 2014-02-10
SI2214487T1 (sl) 2014-03-31
EP2214487B1 (en) 2013-11-27
KR101546111B1 (ko) 2015-08-20
IL204889A (en) 2014-08-31
PL2214487T3 (pl) 2014-04-30
UA107444C2 (uk) 2015-01-12
US20100249137A1 (en) 2010-09-30
RS53180B (en) 2014-06-30
WO2009049157A1 (en) 2009-04-16
CA2702265C (en) 2014-12-02
JP2011500594A (ja) 2011-01-06
ZA201002465B (en) 2010-12-29
EA018414B1 (ru) 2013-07-30
PT2214487E (pt) 2014-02-20
AU2008310732A1 (en) 2009-04-16
HRP20140105T1 (hr) 2014-03-14
BRPI0817542A2 (pt) 2014-10-07
EP2214487A1 (en) 2010-08-11
CR11423A (es) 2010-06-28
JP5372943B2 (ja) 2013-12-18
US8173805B2 (en) 2012-05-08
MA31761B1 (fr) 2010-10-01
CN101896065B (zh) 2013-12-18
NZ584471A (en) 2012-01-12

Similar Documents

Publication Publication Date Title
CY1114865T1 (el) Νεοι αναστολεις seh και η χρηση toyς
CY1121433T1 (el) Παραγωγα δικυκλικων ετεροκυκλυλιων ως αναστολεις irak4
CY1118723T1 (el) Ενωσεις βενζοθειαζολιου και αζαβενζοθειαζολιου χρησιμες ως αναστολεiς κινασης
CY1115738T1 (el) Κρυσταλλικα επιδιαλυτωμενα συμπλοκα των παραγωγων (1s)-1,5-anyδpo-1-c-(3-((φainyλ)meθυλ) φαινυλ)-d-γλουσιτολης με αλκοολες οπως αναστολεις sglt2 για τη θεραπευτικη αντιμετωπιση του διαβητη
EA201000100A1 (ru) Гетероциклические соединения, полезные в качестве ингибиторов mk2
CY1118128T1 (el) Αρυλ διϋδροπυριδινονες και πιπεριδiνονες ως αναστολεις του mgat2
EA201290260A1 (ru) Бензимидазол-имидазольные производные
DE602004008098D1 (de) Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
CY1113038T1 (el) Τριετεροκυκλικες ενωσεις, συνθεσεις, και μεθοδοι για τη θεραπεια καρκινου
CY1116034T1 (el) 2-ανιλινοβενζιμιδαζολο-6-καρβοξαμιδια ως αντι-φλεγμονωδεις παραγοντες
EA200971104A1 (ru) Производные бензимидазола
EA200601896A1 (ru) Производные пролина и их применение в качестве ингибиторов дипептидилпептидазы iv
ECSP066886A (es) Compuestos y métodos para el tratamiento de dislipidemia
TW200745066A (en) Novel PTP1B inhibitors
EA200601350A1 (ru) Азотсодержащие гетероциклические производные и их фармацевтические применения
EA201100311A1 (ru) Амидные производные гетероарилов и их применение в качестве активаторов глюкокиназы
EA200601686A1 (ru) Замещенные производные морфолина и тиоморфолина
NO20062021L (no) Omleirede pentanoler, fremgangsmpte for fremstilling av dette, og deres anvendelse som antiflogistika
EA201170153A1 (ru) Микроциклические производные индола, пригодные в качестве ингибиторов вируса гепатита с
CY1109964T1 (el) Ετεροκυκλικοι δακτυλιοι συντηγμενοι με 1,4-διυδροπυριδινη, η διαδικασια παρασκευης τους, η χρηση και οι συνθεσεις που τους περιεχουν
DE602004008959D1 (de) Benzoäbüä1,4üdioxepinderivate
EA201170617A1 (ru) Пиразолиламинопиридины в качестве ингибиторов fak
EA201001196A1 (ru) Соединения 4-пиридинона и их применение для лечения рака
SA521430330B1 (ar) Eed و rc2 مشتقات آزولوبيريدين كبيرة الحلقة كمعدلات
ATE449776T1 (de) Pyrroloä2,3-cüpyridinderivate